Humana Inc (NYSE:HUM) Receives $343.17 Average PT from Analysts

Humana Inc (NYSE:HUM) has received a consensus rating of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $343.17.

HUM has been the topic of a number of research analyst reports. Morgan Stanley cut their target price on shares of Humana from $331.00 to $315.00 and set an “overweight” rating on the stock in a research report on Friday, July 12th. Piper Jaffray Companies lifted their price target on shares of Humana from $315.00 to $341.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Zacks Investment Research lowered shares of Humana from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. ValuEngine upgraded shares of Humana from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Finally, Credit Suisse Group cut their price target on shares of Humana from $352.00 to $315.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd.

Humana stock traded up $0.86 during mid-day trading on Friday, reaching $287.54. The company had a trading volume of 253,848 shares, compared to its average volume of 1,195,766. Humana has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The firm has a market cap of $39.71 billion, a P/E ratio of 19.76, a P/E/G ratio of 1.27 and a beta of 0.85. The company has a fifty day moving average of $274.58.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, beating analysts’ consensus estimates of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm had revenue of $16.25 billion for the quarter, compared to analyst estimates of $15.88 billion. During the same quarter last year, the business posted $3.96 earnings per share. The company’s quarterly revenue was up 13.9% on a year-over-year basis. Sell-side analysts predict that Humana will post 17.65 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. 1ST Source Bank increased its stake in Humana by 2.8% in the first quarter. 1ST Source Bank now owns 1,414 shares of the insurance provider’s stock valued at $376,000 after purchasing an additional 39 shares in the last quarter. Cornerstone Advisors Inc. grew its holdings in shares of Humana by 13.5% during the second quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock valued at $94,000 after buying an additional 42 shares during the last quarter. Regentatlantic Capital LLC grew its holdings in shares of Humana by 0.4% during the second quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after buying an additional 42 shares during the last quarter. Nachman Norwood & Parrott Inc grew its holdings in shares of Humana by 5.0% during the first quarter. Nachman Norwood & Parrott Inc now owns 1,058 shares of the insurance provider’s stock valued at $281,000 after buying an additional 50 shares during the last quarter. Finally, Kovack Advisors Inc. grew its holdings in shares of Humana by 2.6% during the first quarter. Kovack Advisors Inc. now owns 2,009 shares of the insurance provider’s stock valued at $534,000 after buying an additional 51 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: Different Types of Derivatives

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.